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ABSTRACT
Objective: Breast cancer (BRCA1) is the most common cancer type to women with 5,00,000 deaths in every year worldwide. The purpose of the 
present study is to predict the somatic variants and copy number variants present in BRCA1 genes using 6 paired samples of the glandular tissues.
Methods: In this context, DNA sequencing technology is advanced method used to identify biomarkers that helps patients to have treatment.
Results: From whole genome sequence, several gene mutations are predicted using Annovar and snpEff tools from genome analysis tool kit and 
classified only non-synonymous single nucleotide variants from all datasets and predicted the 28 novel genes that significantly associated with BRCA1.
Conclusion: Results are classified with both breast cells and BRCA1 cells, identified 13 genes which are most commonly expressed and is further used 
for molecular diagnostics.
Keywords: Breast cancer, BRCA1, Non-synonymous single nucleotide variants.
INTRODUCTION
Breast cancer is the most common type of cancer among all other 
cancer types in women [1]. It is been observed that many etiological 
factors are implicated in pathogenesis of breast cancer (BRCA1) [2]. 
Estrogen also acts as a risk factor for breast tumour. Fat rich diet 
and well-cooked meat increase the incidence of BRCA1 [3]. Obesity 
also plays an important role in developing BRCA1 [4]. There are 
several germline gene mutations such as BRCA1 gene also involved 
in BRCA1 [5,6]. Other genes such as p53, PTEN, CHEK2, and ATM 
account for a small proportion of hereditary BRCA1 [7]. RNA-Seq, 
which has a number of edges over conventional expressed sequence 
tag sequencing. Thus, RNA-Seq experiments not only encapsulate the 
transcriptome and also used for measuring expression by replacing 
conventional microarray experiments. Transcriptome sequencing 
(RNA-Seq) possesses many advantages compared to traditional 
microarray technology.
The study reveals the feasibility and readiness of comprehensive genetic 
testing of the BRCA1 gene in an next-generation sequencing (NGS) 
platform for BRCA1 diagnostics. NGS stage is cost effective and time 
powerful and meets the affectability and specificity needs requested 
for hereditary diagnostics, giving NGS and bioinformatics approaches 
arranged to substitute awesome nuclear instruments in endless genetic 
diagnostics setups. Therefore, we have included this in our BRCA1 data 
analysis for disease workflow.
METHODS
Bioinformatics methods are used to analyze the RNA-Seq data from 
different steps such as pre-processing, quality analysis, gene annotation, 
differential gene expression analysis, and variant analysis. Datasets are 
downloaded from ENA and sequence read archive databases. These 
datasets are subjected to quality analysis using FastQC tool. Tophat 
tool is used for gene annotation. Results of Tophat are used to predict 
differential gene expression by Cufflinks. Genome analysis tool kit 
(GATK) is used for variant analysis.
RESULTS AND DISCUSION
The experimental sample of BRCA1 patients with invariant glandular 
tissue and primary infected lymph tumor MRNA sequence is used to 
sequence using the IlluminaMiSeq platform. The overall experiment has 
paired reads of the 6 samples of the glandular tissues is used to predict 
the somatic variants and copy number variants present in BRCA1 gene. 
Further, we need to identify the associated gene functions which are 
expressed in the BRCA1 tissues. The overall raw RNA-Seq datasets is 
listed in Table 1.
FastQC tool I used predict the quality using basic statistical quality 
analysis methods such as mean and median calculation of the box plot 
prediction. During quality filtering of Illumina data generates 65% of 
passed clusters within accepted ranges produce more clusters within 
median range of 14,556,088 to 16,882,897 within the median values 
15,794,284. There is no significant difference in the each replicate with 
statistical t-test of 0.5. The overall sequence data is used further used 
for sequence annotation.
The resultant FastQC trimmed datasets are used to map with reference 
genome sequence (hg18) to ordinate all nucleotides. The overall 
compact of TopHat of multiple reads displays input information has 
22799 sequence read inputs is mapped with reference genome of 
17655 (77.4% of input). Further, cufflinks are used to predict the 
transcriptional regulated genes of exon and functional transcripts 
shows 28,856 exons and 36,185 transcripts are predicted from whole 
genome. To predict total differential expressions, transcript variants 
upregulation and down regulated genes shows 48 gens were breast 
tumor BRCA1 associated genes (Table 3a, b). Based on the differential 
expression of observed Cuffdiff results have three ranges of differential 
expressions CDS overloading differential expressions, promoters 
differential expressions and transcriptional differential expressions. 
We have predicted 1220 upregulated genes and 6858 down regulated 
genes were extracted from all three types of studies.
Using variant analysis of selected upregulated and downregulated 
genes to predict clinical variants of BRCA1 is predicted using Annovar 
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and snpEff tools from GATK predicts several gene mutations from 
whole genome sequence and classified only non-synonymous single 
nucleotide variants from all datasets and extracted to predict the novel 
genes that significantly associated with BRCA1.
From extracted data identified, 28 novel genes is used to predict 
functional annotation and enrichment shows all genes have apoptotic 
character and also associated with certain cancer pathways. Using 
biomarkers, identification of 28 genes is further screened based on the 
functional enrichment analysis and classify with both breast cells and 
BRCA1 cells showed only 13 genes.
Kluska et al. had used the TaqMan SNP genotyping test, the rate of 
5 favored changes, one normal pleomorphism (Q356R), and 4 varieties 
(Q563X, N3124I, c.9118-2G, and c.7249delCA >A) were examined in 
additional gathering of 445 tumor patients analyzed. Despite the fact 
that Q356R was recognized as morbific in ClinVar, its pervasiveness was 
indistinguishable among patients (15.1%) and salubrious ascendances 
(16.9%). By complexity, Q563X was found in 5 (1.1%) out of 445 tumor 
patients, separately; however, just in one salubrious person. The 
3 different varieties (c.7249delCA, c.9118-2G, and N3124I >A) were 
found by TaqMan genotyping just in DNA tests in which they were 
recognized by NGS [8]. In our study, we have identified 13 genes which is 
most commonly expressed and is further used for molecular diagnostics.
CONCLUSION
Our study highlights the differential expression of genes which 
expressed in different tissues of breast cells is predicted using RNA-
Seq analysis. We have characterized the transcriptional factors and 
differential expression of BRCA1 gene that significantly express in 
different cell types. This study reveals the feasibility and readiness of 
Table 1: RNA - Seq read of glandular cells and primary lymph nodes in breast cancer patients
Run Spots Bases Spots Averge 
lengths





ERR687876 22,799 1,14,29,385 22,799 501 5 915 H Paired Female
ERR687877 29,090 1,45,86,611 29,090 501 7 916 H Paired Female
ERR687878 24,454 1,22,59,739 24,454 501 5 903 H Paired Female
ERR687879 34,341 1,72,17,665 34,341 501 8 608 H Paired Female
ERR687880 26,392 13,231,720 26,392 501 6 924 H Paired Female
ERR687881 35,737 1,79,17,269 35,737 501 8 642 H Paired Female
Table 3a: Top upregulated genes in breast cancer glandular tissues
Gene names Term p Count % Fold 
enrichment
FDR
KLHL17 Positive regulation of apoptosis 3.74E-05 43 4.5842 1.9634 0.0667
GPR153 Positive regulation of programmed 
cell death
4.37E-05 43 4.5842 1.9498 0.0779
PEX14 Positive regulation of cell death 4.86E-05 43 4.5842 1.9408 0.0866
FAM131C Induction of apoptosis 2.02E-04 33 3.5181 2.0247 0.3594
Q13209 Induction of programmed cell death 2.13E-04 33 3.5181 2.0184 0.3803
MST1P9 Regulation of apoptosis 0.00,27,447 60 6.3965 1.4652 4.7871
CROCC Regulation of programmed cell death 0.00,34,07,136 60 6.3965 1.4508 5.9096
HSPG2 Regulation of cell death 0.00,37,47,257 60 6.3965 1.4454 6.4811
MYOM3 Induction of apoptosis by 
extracellular signals
0.02,71,00,235 12 1.2793 2.1036 38.7597
RCAN3 Programmed cell death 0.15,33,98,078 38 4.0511 1.2211 94.8807
RHD Apoptosis 0.17,53,08,035 37 3.9445 1.2067 96.7940
Table 3b: Down regulated genes expressed in breast cancer
Gene name Term p Count % Fold 
enrichment
FDR
NBPF10 Actin-binding 6.54E-04 25 2.6652 2.1464 0.9439
ARHGAP29 Actin binding 0.0,01,72,645 31 3.3049 1.8263 2.6608
GCLM Cytoskeleton 0.00,43,40,229 46 4.9040 1.5338 6.1119
SNVs: Single nucleotide variants
Parameters 1 2 3 4 5 6 7 8 9 10
PBSQ 38 38 38 38 38 38 38 38 38 38
PTSQ% 100 100 100 100 100 100 100 100 100 100
PSQS 15,755 15,755 14,379 15,755 15,755 14,379 15,755 15,755 14,379 15,755
OS 0 0 0 0 0 0 0 0 0 0
Adapter 1-239 1-229 1-229 1-245 1-229 1-239 1-229 1-239 1-239 1-229
K-mer 7.86 1.63 9.84 1.483 0 7.49 0 6.49 5.38 0
SNVs: Single nucleotide variants
Table 2: Quality control of RNA-Seq Data using FASTQC server
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genetic testing of BRCA1 associated genes that demand for predicting 
for clinical diagnostics to detect early stage of infection. Finally, we have 
classified the genes that are present in both normal breast cells and 
somatic cell mutation which cause breast tumor.
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